News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
